SNPMiner Trials by Shray Alag


SNPMiner Trials: Clinical Trial Report


Report for Clinical Trial NCT03632317

Developed by Shray Alag, 2019.
SNP Clinical Trial Gene

A Phase 2 Study of Panobinostat in Combination With Everolimus for Children and Young Adults With Gliomas Harboring H3.3 or H3.1 K27M Mutation

This phase 2 trial will evaluate the activity of Panobinostat in combination with Everolimus for children with gliomas harboring H3.1 or H3.3K27M mutation, including newly diagnosed high-grade glioma or DIPG (diffuse intrinsic pontine glioma) after radiation (stratum A) and recurrent/progressive glioma (grade II-IV, including DIPG) (stratum B).

NCT03632317 Glioma Diffuse Intrinsic Pontine Glioma
MeSH: Glioma
HPO: Glioma

2 Interventions

Name: Panobinostat

Description: 30 mg/m^2

Type: Drug

Panobinostat and Everolimus

Name: Everolimus

Description: 3.0 mg/m^2

Type: Drug

Panobinostat and Everolimus


Primary Outcomes

Description: Median PFS at 1 year for stratum A will be measured. Progression is defined as > 25% increase in the size of the tumor or appearance of new lesions.

Measure: Median Progression Free Survival (PFS) at 1 Year

Time: 1year

Description: Median PFS at 1 year for stratum A will be measured. Progression is defined as > 25% increase in the size of the tumor or appearance of new lesions.

Measure: Median Progression Free Survival (PFS) at 2 Years

Time: 2years

Description: The proportion of patients alive at 1 year for stratum A.

Measure: Overall Survival at 1Year

Time: 1year

Description: The proportion of patients alive at 2 years for stratum A.

Measure: Overall Survival at 2Years

Time: 2years

Description: Overall Response Rate (ORR) After Two Cycles of Panobinostat + Everolimus for stratum B. Overall response is defined as a partial or complete response. Partial response is defined as a ≥50% decrease in size of tumor in comparison to baseline measurements. Complete response is defined as the disappearance of all abnormal signal. This includes return to normal size of the brainstem for brainstem lesions.

Measure: Overall Response Rate (ORR) After Two Cycles of Panobinostat + Everolimus

Time: 84 Days

Purpose: Treatment

Single Group Assignment


There is one SNP

SNPs


1 K27M

A Phase 2 Study of Panobinostat in Combination With Everolimus for Children and Young Adults With Gliomas Harboring H3.3 or H3.1 K27M Mutation. --- K27M ---

- H3K27M mutation: Participants must have a mutation in H3.3 K27M or H3.1 K27M as identified by tumor (FFPE or fresh, diagnosis or relapse tissue, but relapse tissue preferred) sequencing, or by CLIA-certified immunohistochemistry staining positive for H3K27M, as defined by review by U of M neuro-pathology. --- K27M ---

- H3K27M mutation: Participants must have a mutation in H3.3 K27M or H3.1 K27M as identified by tumor (FFPE or fresh, diagnosis or relapse tissue, but relapse tissue preferred) sequencing, or by CLIA-certified immunohistochemistry staining positive for H3K27M, as defined by review by U of M neuro-pathology. --- K27M --- --- K27M ---



HPO Nodes


HPO:
Glioma
Genes 30
CHEK2 PMS1 APC MLH1 CDKN2A KRAS TGFBR2 LRP5 NBN MSH6 C11ORF95 ERBB2 RPS20 TSC1 BMPR1A TSC2 RELA PMS2 MSH2 MSH3 MLH3 IDH1 IDH2 SEMA4A NF1 NF2 EPCAM PIK3CA SETBP1 FAN1